一种由黑色素瘤肿瘤细胞呈递给CD8 +肿瘤浸润淋巴细胞的HLA - Cw*0701限制性Melan - A/MART1表位。
A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
作者信息
Larrieu Pierre, Renaud Virginie, Godet Yann, Jotereau Francine, Fonteneau Jean-François
机构信息
Institut de biologie, 9 quai moncousu, 44093, Nantes Cedex, France.
出版信息
Cancer Immunol Immunother. 2008 May;57(5):745-52. doi: 10.1007/s00262-007-0436-7. Epub 2007 Dec 21.
Abstract
Melan-A/MART1 is a melanocytic differentiation antigen recognized on melanoma tumor cells by CD8+ and CD4+ T cells. In this study, we describe a new epitope of this protein recognized in the context of HLA-Cw0701 molecules by a CD8+ tumor infiltrating lymphocyte (TIL) clone. This CD8+ TIL clone specifically recognized and killed a fraction of melanoma cells lines expressing Melan-A/MART1 and HLA-Cw0701. We further show that the Melan-A/MART1(51-61) peptide is the optimal peptide recognized by this clone. Together, these data significantly enlarge the fraction of melanoma patients susceptible to benefit from a Melan-A/MART1 vaccine approach.
摘要
黑色素瘤抗原A/MART1是一种黑色素细胞分化抗原，可被CD8⁺和CD4⁺T细胞识别，存在于黑色素瘤肿瘤细胞上。在本研究中，我们描述了该蛋白的一个新表位，它在HLA - Cw0701分子背景下被一个CD8⁺肿瘤浸润淋巴细胞（TIL）克隆所识别。这个CD8⁺TIL克隆特异性识别并杀伤了一部分表达黑色素瘤抗原A/MART1和HLA - Cw0701的黑色素瘤细胞系。我们进一步表明，黑色素瘤抗原A/MART1(51 - 61)肽是该克隆识别的最佳肽段。这些数据共同显著扩大了可能从黑色素瘤抗原A/MART1疫苗方法中受益的黑色素瘤患者群体。
相似文献
1
A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.一种由黑色素瘤肿瘤细胞呈递给CD8 +肿瘤浸润淋巴细胞的HLA - Cw*0701限制性Melan - A/MART1表位。
Cancer Immunol Immunother. 2008 May;57(5):745-52. doi: 10.1007/s00262-007-0436-7. Epub 2007 Dec 21.
2
A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.一种由黑色素瘤肿瘤细胞呈递给CD4+ T淋巴细胞的HLA-DQ5限制性Melan-A/MART-1表位。
Cancer Immunol Immunother. 2007 Oct;56(10):1565-75. doi: 10.1007/s00262-007-0300-9. Epub 2007 Feb 23.
3
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.黑色素瘤患者中黑色素瘤抗原A/黑色素瘤相关抗原-1特异性CD4 T细胞：新表位的鉴定及通过II类主要组织相容性复合体四聚体对特异性T细胞进行体外可视化分析
J Immunol. 2006 Nov 15;177(10):6769-79. doi: 10.4049/jimmunol.177.10.6769.
4
Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.鉴定出五个源自常见黑色素瘤相关抗原的新的HLA-B*3501限制性表位，这些表位可被肿瘤浸润淋巴细胞自发识别。
J Immunol. 2003 Dec 1;171(11):6283-9. doi: 10.4049/jimmunol.171.11.6283.
5
6
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.TCRβ链使用情况的四聚体引导分析揭示了黑色素瘤患者中大量的黑色素A特异性CD8 + T细胞库。
J Immunol. 2000 Jul 1;165(1):533-8. doi: 10.4049/jimmunol.165.1.533.
7
8
Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.对CD8黑色素瘤浸润淋巴细胞（TIL）识别黑色素瘤相关抗原（MAA）频率的综合分析：对免疫治疗的意义。
Eur J Immunol. 2001 Jul;31(7):2007-15. doi: 10.1002/1521-4141(200107)31:7<2007::aid-immu2007>3.0.co;2-s.
9
10
Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.与HLA - B45.1和HLA - A2.1相关的、被自体细胞溶解性T淋巴细胞识别的黑素细胞分化抗原Melan - A/MART - 1的重叠肽段。
Int J Cancer. 1998 Jan 30;75(3):451-8. doi: 10.1002/(sici)1097-0215(19980130)75:3<451::aid-ijc20>3.0.co;2-a.
引用本文的文献
1
Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.精准靶向癌症：TCR工程化T细胞疗法的策略性见解
Theranostics. 2025 Jan 1;15(1):300-323. doi: 10.7150/thno.104594. eCollection 2025.
2
Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.治疗性癌症疫苗——抗原发现与佐剂递送平台
Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448.
3
Broadening the repertoire of melanoma-associated T-cell epitopes.拓宽黑色素瘤相关T细胞表位的库。
Cancer Immunol Immunother. 2015 May;64(5):609-20. doi: 10.1007/s00262-015-1664-x. Epub 2015 Feb 18.
4
Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule.揭示HLA - C的肽结合特异性：确定任何I类主要组织相容性复合体分子特异性的通用策略。
J Immunol. 2014 Nov 15;193(10):4790-802. doi: 10.4049/jimmunol.1401689. Epub 2014 Oct 13.
5
HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.HLA-A*01:03、HLA-A*24:02、HLA-B*08:01、HLA-B*27:05、HLA-B*35:01、HLA-B*44:02 和 HLA-C*07:01 单链转基因/H-2 类 I 缺失小鼠：人类 T 细胞反应的新型多功能临床前模型。
J Immunol. 2013 Jul 15;191(2):583-93. doi: 10.4049/jimmunol.1300483. Epub 2013 Jun 17.
6
KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.KIR 基因在皮肤恶性黑色素瘤中的变异性：KIR2D/HLA-C 配对对疾病易感性和预后的影响。
Immunogenetics. 2013 May;65(5):333-43. doi: 10.1007/s00251-013-0682-0. Epub 2013 Jan 31.
7
Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.鉴定 HLA-DPB1*0501 限制性 Melan-A/MART-1 表位，该表位被 CD4+ T 淋巴细胞识别：亚洲人群免疫治疗的流行率。
J Immunother. 2011 Sep;34(7):525-34. doi: 10.1097/CJI.0b013e318226bd45.
本文引用的文献
1
Enhancement of human melanoma antigen expression by IFN-beta.干扰素-β增强人黑色素瘤抗原表达
J Immunol. 2007 Aug 15;179(4):2134-42. doi: 10.4049/jimmunol.179.4.2134.
2
A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.一种由黑色素瘤肿瘤细胞呈递给CD4+ T淋巴细胞的HLA-DQ5限制性Melan-A/MART-1表位。
Cancer Immunol Immunother. 2007 Oct;56(10):1565-75. doi: 10.1007/s00262-007-0300-9. Epub 2007 Feb 23.
3
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.黑色素瘤患者中黑色素瘤抗原A/黑色素瘤相关抗原-1特异性CD4 T细胞：新表位的鉴定及通过II类主要组织相容性复合体四聚体对特异性T细胞进行体外可视化分析
J Immunol. 2006 Nov 15;177(10):6769-79. doi: 10.4049/jimmunol.177.10.6769.
4
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.负载灭活同种异体黑色素瘤细胞的树突状细胞可诱导客观临床反应和MART-1特异性CD8 + T细胞免疫。
J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b.
5
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.输注黑色素瘤抗原A/MART-1特异性肿瘤浸润淋巴细胞可提高黑色素瘤患者的无复发生存率。
Cancer Immunol Immunother. 2007 Apr;56(4):515-26. doi: 10.1007/s00262-006-0204-0. Epub 2006 Jul 28.
6
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.由频繁表达的II类主要组织相容性复合体（MHC）等位基因呈递的两个黑色素瘤抗原A（Melan-A）CD4 + T细胞表位的鉴定
Clin Immunol. 2006 Oct;121(1):54-62. doi: 10.1016/j.clim.2006.05.007. Epub 2006 Jun 30.
7
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.在黑色素瘤患者中过继转移肿瘤反应性黑色素瘤抗原（Melan-A）特异性细胞毒性T淋巴细胞（CTL）克隆后，其他Melan-A特异性T细胞的频率增加。
J Immunol. 2005 Oct 1;175(7):4797-805. doi: 10.4049/jimmunol.175.7.4797.
8
A listing of human tumor antigens recognized by T cells: March 2004 update.T细胞识别的人类肿瘤抗原列表：2004年3月更新
Cancer Immunol Immunother. 2005 Mar;54(3):187-207. doi: 10.1007/s00262-004-0560-6. Epub 2004 Aug 7.
9
Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.利用慢病毒转导的树突状细胞鉴定由HLA-Cw7呈递并由多个MAGE基因编码的新抗原肽。
J Immunol. 2004 Feb 15;172(4):2232-7. doi: 10.4049/jimmunol.172.4.2232.
10
Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.鉴定出五个源自常见黑色素瘤相关抗原的新的HLA-B*3501限制性表位，这些表位可被肿瘤浸润淋巴细胞自发识别。
J Immunol. 2003 Dec 1;171(11):6283-9. doi: 10.4049/jimmunol.171.11.6283.
Zotero 插件